Trends in vaccine adjuvants

References

• Ramon G. Diphtheria toxin and anatoxin. Ann. Inst. Pasteur.38, 1 (1924).
   Google Scholar
• Caccamo N, Guggino G, Joosten SA et al. Multifunctional CD4+ T cells correlate with active Mycobacterium tuberculosis infection. Eur. J. Immunol.40(8), 2211–2220 (2010).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine21(24), 3479–3482 (2003).
   PubMed Web of Science ®Google Scholar
• Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl Acad. Sci. USA107(46), 19985–19990 (2010).
   PubMed Web of Science ®Google Scholar
• Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev.222, 129–144 (2008).
   PubMed Web of Science ®Google Scholar
• Rinaudo CD, Telford JL, Rappuoli R, Seib KL. Vaccinology in the genome era. J. Clin. Invest.119(9), 2515–2525 (2009).
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science287(5459), 1816–1820 (2000).
   PubMed Web of Science ®Google Scholar
• Moriel DG, Bertoldi I, Spagnuolo A et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc. Natl Acad. Sci. USA1107(20), 9072–9077 (2010).
   Google Scholar
• Maione D, Margarit I, Rinaudo CD et al. Identification of a universal Group B Streptococcus vaccine by multiple genome screen. Science309(5731), 148–150 (2005).
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J. Low. Genit. Tract Dis.14(2), 124–129 (2010).
   PubMed Web of Science ®Google Scholar
• Le Moignic P. Les vaccins en emulsion dans les corps gras ou “lipo-vaccins”. Comptes C. R. Seances Soc. Biol. Fil.79, 201–203 (1916).
   Google Scholar
• Glenny AT, Pope C, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol.29, 28–45 (1926).
   Google Scholar
• Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity29(3), 319–324 (2008).
   PubMed Web of Science ®Google Scholar
• Kalinski P, Hilkens CM, Wieringa EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol. Today20, 561–567 (1999).
   PubMedGoogle Scholar
• Bluestone JA, Mackay CR, O’Shea JJ. Stockinger B. The functional plasticity of T cell subsets. Nat. Rev. Immunol.9, 811–816 (2009).
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol.3, 133–146 (2003).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, McMichael AJ. Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nat. Med.11, S33–S44 (2005).
   PubMed Web of Science ®Google Scholar
• Stevenson MM, Riley EM. Innate immunity to malaria. Nat. Rev. Immunol.4, 169–180 (2004).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug. Discov.5, 471–484 (2006).
   PubMed Web of Science ®Google Scholar
• Happel KI, Dubin PJ, Zheng M et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med.202, 761–769 (2005).
   PubMed Web of Science ®Google Scholar
• Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol.8, 337–348 (2008).
   PubMed Web of Science ®Google Scholar
• King C. New insights into the differentiation and function of T follicular helper cells. Nat. Rev. Immunol.9(11), 757–766 (2009).
   PubMed Web of Science ®Google Scholar
• Jerne NK. The generative grammar of the immune system. EMBO J.4, 847–852 (1985).
   PubMedGoogle Scholar
• Schijns VEJC. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol.21, 75–85 (2001).
   PubMed Web of Science ®Google Scholar
• Schijns VEJC. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol.12, 456–463 (2000).
   PubMed Web of Science ®Google Scholar
• Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine18(5–6), 434–439 (1999).
   PubMed Web of Science ®Google Scholar
• Tanaka T, Legat A, Adam E et al. DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur. J. Immunol.38(5), 1351–1357 (2008).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol. Rev.156, 199–209 (1997).
   PubMed Web of Science ®Google Scholar
• Herbert WJ. Antigenicity of soluble protein in the presence of high levels of antibody: a possible mode of action of the antigen adjuvants. Nature210, 747–748 (1966).
   PubMed Web of Science ®Google Scholar
• Herbert WJ. The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunology14, 301–318 (1968).
   PubMed Web of Science ®Google Scholar
• Holm BC, Svelander L, Bucht A, Lorentzen JC. The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes. Clin. Exp. Immunol.127, 430–435 (2002).
   PubMed Web of Science ®Google Scholar
• Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol.180, 5402–5412 (2004).
   Google Scholar
• Mosca F, Tritto E, Muzzi A et al. molecular and cellular signatures of human adjuvants Proc. Natl Acad. Sci. USA105, 10501–10506 (2008).
   PubMed Web of Science ®Google Scholar
• Phythian-Adams AT, Cook PC, Lundie RJ et al. CD11c depletion severely disrupts Th2 induction and development in vivo. J. Exp. Med.207(10), 2089–2096 (2010).
   PubMed Web of Science ®Google Scholar
• Neill DR, Wong SH, Bellosi A et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature464(7293), 1367–1370 (2010).
   PubMed Web of Science ®Google Scholar
• Kool M, Soullié T, van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med.205(4), 869–882 (2008).
   PubMed Web of Science ®Google Scholar
• Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science304(5678), 1808–1810 (2004).
   PubMed Web of Science ®Google Scholar
• Eng NF, Garlapati S, Gerdts V, Potter A, Babiuk LA, Mutwiri GK. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents. Curr. Drug Deliv.7(1), 13–20 (2010).
   PubMedGoogle Scholar
• Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine24(19), 4179–4187 (2006).
   PubMed Web of Science ®Google Scholar
• Lavelle EC, O’Hagan DT. Delivery systems and adjuvants for oral vaccines. Expert Opin. Drug Deliv.3(6), 747–762 (2006).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol. Today13, 11–16 (1992).
   PubMedGoogle Scholar
• Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science282, 2085–2088 (1998).
   PubMed Web of Science ®Google Scholar
• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu. Rev. Immunol.21, 335–376 (2003).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol.54, 1–13 (1989).
   PubMedGoogle Scholar
• Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol.183(10), 6186–6197 (2009).
   PubMed Web of Science ®Google Scholar
• Gavin AL, Hoebe K, Duong B et al. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science314, 1936–1938 (2006).
   PubMed Web of Science ®Google Scholar
• McKee AS, Munks MW, MacLeod MK et al. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J. Immunol.183(7), 4403–4414 (2009).
   PubMed Web of Science ®Google Scholar
• Calabro S, Tortoli M, Baudner BC et al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine29(9), 1812–1823 (2011).
   PubMed Web of Science ®Google Scholar
• Ting JP, Lovering RC, Alnemri ES et al. The NLR gene family: a standard nomenclature. Immunity28(3), 285–287 (2008).
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Ishikawa T, Morita YS et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med.206(13), 2879–2888 (2009).
   PubMed Web of Science ®Google Scholar
• Schoenen H, Bodendorfer B, Hitchens K et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol.184(6), 2756–2760 (2010).
   PubMed Web of Science ®Google Scholar
• Brown GD, Gordon S. Immune recognition. A new receptor for β-glucans. Nature413(6851), 36–37 (2001).
   PubMed Web of Science ®Google Scholar
• Brown GD, Herre J, Williams DL, Willment JA, Marshall AS, Gordon S. Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med.197(9), 1119–1124 (2003).
   PubMed Web of Science ®Google Scholar
• Unterholzner L, Keating SE, Baran M et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol.11(11), 997–1004 (2010).
   PubMed Web of Science ®Google Scholar
• Goodridge HS, Underhill DM. Fungal Recognition by TLR2 and Dectin-1. Handb. Exp. Pharmacol.183, 87–109 (2008).
   Google Scholar
• Ma R, Du JL, Huang J, Chang-you W. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination. Biochem. Biophys. Res. Commun.361(2), 537–542 (2007).
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger and the extended family. Ann. Rev. Immunol.12, 991–1045 (1994).
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature425(6957), 516–521 (2003).
   PubMed Web of Science ®Google Scholar
• Harris J, Sharp FA, Lavelle EC. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur. J. Immunol.40(3), 634–638 (2010).
   PubMed Web of Science ®Google Scholar
• Kool M, Pétrilli V, De Smedt T et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol.181(6), 3755–3759 (2008).
   PubMed Web of Science ®Google Scholar
• Franchi L, Núñez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity. Eur. J. Immunol.38(8), 2085–2089 (2008).
   PubMed Web of Science ®Google Scholar
• Sharp FA, Ruane D, Claass B et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci. USA106, 80–875 (2009).
   Google Scholar
• Gross O, Poeck H, Bscheider M et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature459(7245), 433–436 (2009).
   PubMed Web of Science ®Google Scholar
• Allen IC, Scull MA, Moore CB et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity30(4), 556–565 (2009).
   PubMed Web of Science ®Google Scholar
• Willingham SB, Allen IC, Bergstralh DT et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J. Immunol.183(3), 2008–2015 (2009).
   PubMed Web of Science ®Google Scholar
• McNeela EA, Burke Á, Neill DR et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog.6(11), e1001191 (2010).
   PubMed Web of Science ®Google Scholar
• Broz P, Newton K, Lamkanfi M, Mariathasan S, Dixit VM, Monack DM. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J. Exp. Med.207(8), 1745–1755 (2010).
   PubMedGoogle Scholar
• Morein B, Villacrés-Eriksson M, Lövgren-Bengtsson K. Iscom, a delivery system for parenteral and mucosal vaccination. Dev. Biol. Stand.92, 33–39 (1998).
   PubMedGoogle Scholar
• Aichinger MC, Ginzler M, Weghuber J et al. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Vaccine29(3), 426–436 (2010).
   PubMedGoogle Scholar
• Lay M, Callejo B, Chang S et al. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity and antigenically drifted protection. Vaccine27(29), 3811–3820 (2009).
   PubMed Web of Science ®Google Scholar
• Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood113(17), 3969–3977 (2009).
   PubMed Web of Science ®Google Scholar
• Kamath AT, Valenti MP, Rochat AF et al. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells. Eur. J. Immunol.38(5), 1247–1256 (2008).
   PubMedGoogle Scholar
• Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine26(4), 552–561 (2008).
   PubMed Web of Science ®Google Scholar
• Chabalgoity JA, Baz A, Rial A, Grille S. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev.18, 195–207 (2007).
   PubMed Web of Science ®Google Scholar
• Wickelgren I. Mouse studies question importance of Toll-like receptors to vaccines. Science314, 1859–1860 (2006).
   PubMedGoogle Scholar
• Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol.27(12), 573–579 (2006).
   PubMed Web of Science ®Google Scholar
• Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med.199(6), 815–824 (2004).
   PubMed Web of Science ®Google Scholar
• Wang RF, Wang HY. Enhancement of antitumor immunity by prolonging antigen presentation on dendritic cells. Nat. Biotechnol.20(2), 149–154 (2002).
   PubMed Web of Science ®Google Scholar
• Jansen T, Hofmans MP, Theelen MJ, Schijns VEJC. Structure-activity relations of water-in-oil vaccine formulations and induced antigen-specific antibody responses. Vaccine 11, 23(8), 1053–1060 (2005).
   PubMed Web of Science ®Google Scholar
• Jansen T, Hofmans MP, Theelen MJ, Manders FG, Schijns VEJC. Dose and timing requirements for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function. Avian Pathol.36(5), 361–365 (2007).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov.2(9), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Guy B. The prefect mix: recent progress in adjuvant research. Nat. Rev. Micr.5(7), 505–517 (2007).
   PubMed Web of Science ®Google Scholar
• Mizel SB, Bates JT. Flagellin as an adjuvant: cellular mechanisms and potential. J. Immunol.185(10), 5677–5682 (2010).
   PubMed Web of Science ®Google Scholar
• Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation. Blood113(17), 3969–3977 (2009).
   PubMed Web of Science ®Google Scholar
• Kapadia D, Fong L. CTLA-4 blockade: autoimmunity as treatment. J. Clin. Oncol.23, 8926–8928 (2005).
   PubMedGoogle Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat. Rev. Immunol.10(3), 170–181 (2010).
   PubMed Web of Science ®Google Scholar
• Yang L, Pang Y, Moses HL. TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol.31(6), 220–227 (2010).
   PubMed Web of Science ®Google Scholar
• Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol.9, 185–194 (2009).
   PubMed Web of Science ®Google Scholar